Rivus Pharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
HU6 / Rivus Pharma
HFpEF, NCT05284617: Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese

Completed
2
67
US
HU6, Placebo
Rivus Pharmaceuticals, Inc.
Heart Failure With Preserved Ejection Fraction
05/24
05/24
NCT05979779: Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis

Active, not recruiting
2
219
US
HU6, Placebo
Rivus Pharmaceuticals, Inc.
Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver
02/25
04/25
NCT06104358: Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes

Withdrawn
2
48
US
HU6
Rivus Pharmaceuticals, Inc.
Diabete Type 2, Obesity
02/25
03/25
NCT05433506: Safety and Pharmacokinetics of HU6

Completed
1
30
US
HU6 Tablet, HU6 Capsule
Rivus Pharmaceuticals, Inc.
Obese
01/23
03/23
NCT06325930: A Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-HU6

Completed
1
8
US
[14C]-HU6
Rivus Pharmaceuticals, Inc.
Healthy
05/24
05/24
NCT06486558: Relative Bioavailability Study of HU6

Recruiting
1
40
US
HU6 450 mg Tablet, HU6 150 mg Capsules x 3 (Total dose = 450 mg)
Rivus Pharmaceuticals, Inc.
Healthy
10/24
10/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
HU6 / Rivus Pharma
HFpEF, NCT05284617: Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese

Completed
2
67
US
HU6, Placebo
Rivus Pharmaceuticals, Inc.
Heart Failure With Preserved Ejection Fraction
05/24
05/24
NCT05979779: Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis

Active, not recruiting
2
219
US
HU6, Placebo
Rivus Pharmaceuticals, Inc.
Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver
02/25
04/25
NCT06104358: Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes

Withdrawn
2
48
US
HU6
Rivus Pharmaceuticals, Inc.
Diabete Type 2, Obesity
02/25
03/25
NCT05433506: Safety and Pharmacokinetics of HU6

Completed
1
30
US
HU6 Tablet, HU6 Capsule
Rivus Pharmaceuticals, Inc.
Obese
01/23
03/23
NCT06325930: A Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-HU6

Completed
1
8
US
[14C]-HU6
Rivus Pharmaceuticals, Inc.
Healthy
05/24
05/24
NCT06486558: Relative Bioavailability Study of HU6

Recruiting
1
40
US
HU6 450 mg Tablet, HU6 150 mg Capsules x 3 (Total dose = 450 mg)
Rivus Pharmaceuticals, Inc.
Healthy
10/24
10/24

Download Options